INTRODUCTION
There is circumstantial evidence that population-based screening programmes can reduce breast cancer mortality in women aged 40-70 years old. The value of screening in highrisk groups such as women with a positive family history of breast cancer is unproven.
In the meantime a rapidly increasing number of high-risk women seek counselling about strategies to reduce their risk of breast cancer death, such as intensive surveillance. As for ethical reasons no randomized trials can be performed, the effect of screening these women has to be evaluated by means of observational studies. In several specialized centers in the Netherlands, women with a more than 2 times increased risk of breast cancer (BC) (lifetime > 15%) are being screened regularly.
In this study the first results of screening highrisk women in the Rotterdam Cancer Center/ University Hospital are described.
PATIENTS AND METHODS
According to Dutch national guidelines, highrisk women are screened by (at least) biannual clinical breast examination (CBE) and yearly mammography. The minimum age at entry is 25 years. When indicated, additional investigations by ultrasound and/or MRI are performed. A database was set up in which family and individual characteristics, screening data and final outcome of screening are registered. To date, 810 women were screened at least once.
By means of DNA-diagnosis or geneticepidemiologic tables [1] , three risk groups were defined (see Table 1 ).
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FOLLOW-UP
Two patients (1 and 9) relapsed; both died of metastatic disease 2.5 and 4 years, respectively, after the diagnosis. One additional patient (4) died of another cause (CML).
SUMMARY MEASURES
See Table 4 .
CONCLUSIONS
It is possible to identify young women at high familial risk for breast cancer. The number of cancers detected in this population was on average 5 times greater than expected and related to the risk category.
Data will be included in a national multi-centre study to assess the short-term results of screening and predict long-term effects, such as mortality reduction. Further, the value of MRI as a potential alternative for mammography will be investigated. (1/13) Sensitivity = a/a + c with a defined as:
1) all screen-detected tumours (n = 14) 78% (14/18) 2) asymptomatic screen-detected (n = 11) 61% (11/18)
